236 related articles for article (PubMed ID: 14512321)
1. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.
Gurbuxani S; Vyas P; Crispino JD
Blood; 2004 Jan; 103(2):399-406. PubMed ID: 14512321
[TBL] [Abstract][Full Text] [Related]
2. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
3. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
[TBL] [Abstract][Full Text] [Related]
4. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
5. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
Mundschau G; Gurbuxani S; Gamis AS; Greene ME; Arceci RJ; Crispino JD
Blood; 2003 Jun; 101(11):4298-300. PubMed ID: 12560215
[TBL] [Abstract][Full Text] [Related]
6. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
7. GATA1 in normal and malignant hematopoiesis.
Crispino JD
Semin Cell Dev Biol; 2005 Feb; 16(1):137-47. PubMed ID: 15659348
[TBL] [Abstract][Full Text] [Related]
8. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
Crispino JD
Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
[TBL] [Abstract][Full Text] [Related]
9. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
[TBL] [Abstract][Full Text] [Related]
10. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
[TBL] [Abstract][Full Text] [Related]
11. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.
Hitzler JK; Cheung J; Li Y; Scherer SW; Zipursky A
Blood; 2003 Jun; 101(11):4301-4. PubMed ID: 12586620
[TBL] [Abstract][Full Text] [Related]
12. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.
Groet J; McElwaine S; Spinelli M; Rinaldi A; Burtscher I; Mulligan C; Mensah A; Cavani S; Dagna-Bricarelli F; Basso G; Cotter FE; Nizetic D
Lancet; 2003 May; 361(9369):1617-20. PubMed ID: 12747884
[TBL] [Abstract][Full Text] [Related]
13. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
[TBL] [Abstract][Full Text] [Related]
14. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
15. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
Alford KA; Reinhardt K; Garnett C; Norton A; Böhmer K; von Neuhoff C; Kolenova A; Marchi E; Klusmann JH; Roberts I; Hasle H; Reinhardt D; Vyas P;
Blood; 2011 Aug; 118(8):2222-38. PubMed ID: 21715302
[TBL] [Abstract][Full Text] [Related]
16. Transcription factor GATA-1 and Down syndrome leukemogenesis.
Muntean AG; Ge Y; Taub JW; Crispino JD
Leuk Lymphoma; 2006 Jun; 47(6):986-97. PubMed ID: 16840187
[TBL] [Abstract][Full Text] [Related]
17. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
[TBL] [Abstract][Full Text] [Related]
18. Myeloid leukemia in Down syndrome.
Khan I; Malinge S; Crispino J
Crit Rev Oncog; 2011; 16(1-2):25-36. PubMed ID: 22150305
[TBL] [Abstract][Full Text] [Related]
19. Evolution of myeloid leukemia in children with Down syndrome.
Saida S
Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
[TBL] [Abstract][Full Text] [Related]
20. Analysis of GATA1 mutations and leukemogenesis in newborns with Down syndrome.
Queiroz LB; Lima BD; Mazzeu JF; Camargo R; Córdoba MS; Q Magalhães I; Martins-de-Sá C; Ferrari I
Genet Mol Res; 2013 Oct; 12(4):4630-8. PubMed ID: 24222239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
